Zydus Cadila gets final US FDA nod to market arthritis drugs

It will manufacture the drug at the Moraiya facility in Ahmedabad

Zydus Cadilla, healthcare, Sentynl, Ahmedabad — <b>BUYING SPREE:</b> This is the fifth product and company acquisition by Zydus in 12 months

Last Updated : Sep 27 2017 | 1:09 PM IST

Drug firm Zydus Cadila today said it has received final approval from the US health regulator to market indomethacin extended release capsules used in treating painful and inflammatory conditions such as arthritis.

The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 75 mg, it said in a BSE filing.

It will manufacture the drug at the Moraiya facility in Ahmedabad.

Zydus Cadila gets USFDA nod to market anti-dementia drug

Zydus Cadila gets US health regulator nod to market Mycophenolate Mofetil

Zydus Cadila gets USFDA nod for high blood pressure, heart disorder drug

Troubles behind it, Cadila surges ahead

Zydus Cadila gets USFDA nod for drug used to reduce risk of strokes

Zydus Cadila said it has more than 155 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.

Shares of the company's listed entity Cadila Healthcare were trading 2.70 per cent down at Rs 461.50 per scrip on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Already subscribed? Log in

Subscribe to read the full story →

^*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

In-depth market analysis & insights with access to The Smart Investor

Ad-free Reading

Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

Access Business Standard across devices — mobile, tablet, or PC, via web or app